28 February 2017

NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT

Final agenda

The meeting will start promptly at 10:00 and is expected to finish at approximately 16:00.

Please note that this agenda is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Apologies – Part 1 only (open session)
  3. Any other business – Part 1 only (open session)
  4. Appraisal of collagenase clostridium histolyticum for treating Dupuytren’s contractureThe Committee for Medicinal Products for Human Use (at European Medicines Agency) has not yet given its regulatory opinion for nivolumab and as a consequence this discussion will take place in a Part 2 session (Part 2 sessions are closed to public observers).
    • 4.1. Declarations of interest – Part 2 only (closed session)
    • 4.2. Introduction by the Chair, Professor Gary McVeigh – Part 2 only (closed session)
    • 4.3. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  5. Appraisal of everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression
    • 5.1. Declarations of interest – Part 1 only (open session)
    • 5.2. Introduction by the Chair, Professor Gary McVeigh – Part 1 only (open session)
    • 5.3. Presentation by the lead team – Part 1 AND part 2 (open and closed session)
    • 5.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  6. Appraisal of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapyThis discussion will focus on a new value proposition submitted by the company. The nature of this discussion is commercially sensitive and will take place in part 2 only (Part 2 sessions are closed to public observers).
    • 6.1. Declarations of interest – Part 2 only (closed session)
    • 6.2. Introduction by the Chair, Professor Gary McVeigh – Part 2 only (closed session)
    • 6.3. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs
    • 7.1. Declarations of interest – Part 1 only (open session)
    • 7.2. Introduction by the Vice Chair, Dr Lindsay Smith – Part 1 only (open session)
    • 7.3. Presentation by the Vice Chair, Dr Lindsay Smith – Part 1 AND part 2 (open and closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Wednesday 29 March 2017 at NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT.

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Tuesday 14 February 2017Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Jon Littler.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 31 January 2017 to 14 February 2017
Registration is closed.